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Objectives: To describe the patient populations and infections being treated with daptomycin, as well as the
efﬁcacy and safety outcomes.
Patients and methods: Data from the European Cubicin Outcomes Registry and Experience (EU-CORE
SM), retro-
spectively collected at 118 institutions between January 2006 and August 2008, were analysed.
Results: Daptomycin treatment was documented in 1127 patients with diverse infections, including compli-
cated skin and soft tissue infections (33%), bacteraemia (22%), endocarditis (12%) and osteomyelitis (6%).
It was used empirically, before microbiological results became available, in 53% of patients. Staphylococcus
aureus was the most common pathogen (34%), with 52% of isolates resistant to methicillin; coagulase-
negative staphylococci and enterococci were also frequent, with 22% of Enterococcus faecium isolates resistant
to vancomycin. Daptomycin was used as ﬁrst-line therapy in 302 (27%) patients. When used second line, the
most common reasons for discontinuation of previous antibiotic were treatment failure and toxicity or intoler-
ance. The use of concomitant antibiotics was reported in 65% of patients. Most frequent doses were 6 mg/kg
(47%) and 4 mg/kg (32%). The median duration of daptomycin therapy was 10 days (range 1–246 days) in the
inpatient setting and 13 days (range 2–189 days) in the outpatient setting. The overall clinical success rate was
79%, with a clinical failure rate of ,10% for all infection types. Low failure rates were observed in ﬁrst- and
second-line therapy (6% and 8%, respectively). Daptomycin demonstrated a favourable safety and tolerability
proﬁle regardless of treatment duration.
Conclusions: Daptomycin has a relevant role in the treatment of Gram-positive infections.
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Introduction
Daptomycin (Cubicin
w), the ﬁrst-in-class cyclic lipopeptide anti-
biotic, was approved in Europe for the treatment of complicated
skin and soft tissue infections (cSSTIs) in 2006 and for the treat-
ment of right-sided infective endocarditis (RIE) due to
Staphylococcus aureus and S. aureus bacteraemia (SAB) when
associated with RIE or with cSSTI in 2007.
1 By mid-2010, dapto-
mycin had been used to treat an estimated 1000000 patients
with serious Gram-positive infections worldwide.
2 The clinical
experience with daptomycin in Europe since its approval has
been captured by the European Cubicin Outcomes Registry and
Experience (EU-CORE
SM)—a multicentre, retrospective, non-
interventional registry sponsored by Novartis Pharma AG.
EU-CORE was designed to collect data on the characteristics
[patient population, infections, pathogens and adverse events
(AEs)] and clinical outcomes of patients receiving daptomycin.
It mirrors the Cubicin Outcomes Registry and Experience
(CORE
w)—an ongoing programme that has been conducted by
Cubist Pharmaceuticals to describe the experience with dapto-
mycin in the USA, the methodology for which is described else-
where.
3–5 The primary objectives of the EU-CORE programme
are: to characterize and describe the population of patients
receiving daptomycin and the infections and pathogens treated
with daptomycin in the clinical setting; to evaluate the clinical
outcomes of daptomycin therapy; to characterize, describe and
evaluate the safety and tolerability of daptomycin; and to
describe daptomycin prescribing patterns. Any institution at
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912which patients have received at least one dose of commercially
available daptomycin since 2006 can participate. Data collection
will always reﬂect up-to-date clinical practice, as the three data
collection periods were deﬁned in the study protocol, which was
ﬁnalized in 2007, as follows: ﬁrst collection period including
patients treated after ﬁrst regulatory approval in Europe in early
2006 until summer 2008, second period from summer 2008 to
summer 2009, and third collection period from summer 2009
to summer 2010. This will allow for comparison of patterns of
clinical use of daptomycin over time. Yearly database locks were
planned to occur at the end of September 2008, 2009 and
2010. It is expected that each database lock will include data
from  1000–1400 patients. Documented cases of patients who
completed daptomycin treatment, including a minimum post-
treatment observation period of 30 days until 1 month before
the yearly database lock, will be included in each of the respective
collection periods as well as in the ﬁnal study analysis.
The efﬁcacy and safety of daptomycin have been established in
clinical trials in cSSTIs
6 and in SAB with or without infective endo-
carditis (IE).
7 However, because of their rigorous nature (e.g.
inclusion and exclusion criteria and the requirement for protocol
adherence), clinical trials may not always reﬂect the true experi-
ence with a drug in clinical practice.
8 Patient registries such as
EU-CORE provide insight into real-world clinical experience with
daptomycin and build on the evidence base from clinical trials.
This report describes the data from the ﬁrst 2.5 years of daptomy-
cin use for the treatment of Gram-positive infections from ﬁrst
European approval on 19 January 2006 until 31 August 2008.
Patients and methods
Patients and data collection
The purpose of this study is to collect real-world data about the non-
controlled prescribing use and impact of daptomycin. Therefore, a
non-interventional, multicentre, retrospective design was chosen.
Investigators were asked to voluntarily include as many patients as avail-
able. Patients could be retrospectively included if they were treated with
at least one dose of daptomycin and if all relevant information was
entered in the case report form (CRF). Patients who received daptomycin
as part of a controlled clinical trial were not eligible for inclusion. Inves-
tigators at .100 institutions across Europe collected anonymous demo-
graphic, antibiotic, microbiological and clinical data from medical records
using a standardized CRF and protocol. Argentinean sites were also
allowed to participate, as overall enrolment predictions were uncertain
and daptomycin had just been approved in that country. Written
informed consent that complies with the ICH Good Clinical Practice
guideline was obtained if required by the institutional review board or
ethics committee and/or local data privacy regulations, and the protocol
was approved by the health authority and the institutional review board
or ethics committee, as required, in each country. Investigators were
trained on the CRF and received written instructions to further guide
the collection of patient data. Each patient is uniquely identiﬁed in the
study by a combination of his/her centre number and patient number.
All data are entered on standardized CRFs exclusively according to the
investigator’s judgement. Data from the CRFs are entered into the
study database by certiﬁed contract research organization staff
working on behalf of the sponsor. After database lock, all available
data were distributed to all authors of the manuscript, who take part
in scheduled publication committee meetings. All information collected
reﬂected standard practice in each site. There was no intervention or
restriction in clinical practice. Patient data can be recorded into this
registry after a minimum of 30 days from the end of daptomycin
therapy to permit the capture of AEs/serious AEs (SAEs). The CRFs col-
lected the following information: treatment period; demographics;
underlying diseases; pregnancy; neutropenia; antimicrobials; use of
other antibiotics and statins; renal function; creatine phosphokinase
(CPK) concentrations; diagnosis and current infection details; doses of
current antibiotic treatment; duration of inpatient and/or outpatient
treatment; outcomes; AEs and SAEs occurring between treatment
onset and 30 days after last dose of daptomycin; and discharge infor-
mation. No instructions were provided concerning drug discontinuation,
study completion or post-study treatment. However, the reasons for
study drug discontinuation, reason for completion of daptomycin treat-
ment and antibiotic use after daptomycin treatment were captured. In
cases of multiple infection, investigators entered the type of infection
in order of clinical signiﬁcance (i.e. primary or secondary infection) for
which the patient received daptomycin.
In the database, the primary infection was always automatically
assigned to the disease of higher hierarchy according to the following
predeﬁned severity classiﬁcation (in order of most to least severe): endo-
carditis; osteomyelitis; bacteraemia; other [CNS infection, foreign body/
prosthetic infection, metastatic abscess, necrotizing fasciitis, necrotizing
infection, surgical/non-surgical antibiotic prophylaxis, septic arthritis
and urinary tract infection (UTI)/pyelonephritis]; cSSTI; uncomplicated
skin and soft tissue infection (uSSTI). This classiﬁcation was needed to
allow for analysis standardization and was based on experts’ and spon-
sor’s judgement taking into consideration clinical prognosis, probability of
microbiology eradication and consequences of treatment failure. Safety
analysis included all reports of AEs, the severity of which was determined
by the investigators. AEs were recorded regardless of their relationship to
daptomycin therapy. The overall methodology of this registry, including
the deﬁnitions mentioned in the following section, is aligned with the
CORE registry methodology. It is possible to merge the databases to
perform combined or comparative analyses between different regions,
as recently published by Gonzalez-Ruiz et al.
9
Deﬁnitions
Clinical outcomes at the end of daptomycin therapy were assessed by
investigators using the following protocol-deﬁned criteria: cure—clinical
signs and symptoms resolved and/or no additional antibiotic therapy
necessary, or negative culture reported at the end of therapy;
improved—partial resolution of clinical signs and symptoms and/or
additional antibiotic therapy warranted at the end of therapy; failure—
inadequate response to therapy, worsening or new/recurrent signs and
symptoms, need for a change in antibiotic therapy, or positive culture
reported at the end of therapy; and non-evaluable, unable to determine
response due to insufﬁcient information. The term clinical success was
used to describe patients with an outcome of cure or improved. The
safety population included all documented patients who received at
least one dose of daptomycin and for whom any safety parameters
were assessed (the statement that no AEs occurred was considered a
valid assessment). The efﬁcacy population included all documented
patients who received at least one dose of daptomycin and for whom
clinical outcome was assessed.
Results
Patient demographics and clinical characteristics
A total of 116 institutions in Europe and two institutions in
Argentina registered patients in the study during the report
period. The largest number of sites was in Spain, 49 in total
spread across the country. Countries with 10–20 sites were
Germany, Greece and the UK. Fewer than 10 sites were registered
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JACin Austria, France, Italy and Slovenia. A total of 1127 patients
were registered in the EU-CORE database during the reporting
period, all of whom were included in both the efﬁcacy and
safety populations. Only eight patients from Argentina were
included; therefore, the reported results largely reﬂect European
use of the drug. Patients had a mean age of 59.2 years (range 1–
93 years), with 46% of patients aged ≥65 years; a mean body
weight of 75.4 kg (range 6–180 kg); and the majority (64%) of
patients were male (Table 1). Hypertension and diabetes mellitus
were the most common signiﬁcant underlying diseases,
occurring in 30% and 26% of patients, respectively. Other fre-
quent underlying co-morbid conditions included cancer (14%)
and chronic renal failure (13%), and 14% of patients had a crea-
tinine clearance (CLCR)o f,30 mL/min.
Of the wide range of primary infection types treated with dap-
tomycin, cSSTIs were the most frequent, accounting for 33% of
the patient population. Patients with bacteraemia (n¼244;
22%), endocarditis (n¼136; 12%), uSSTI (n¼123; 11%), osteo-
myelitis (n¼64; 6%) and infections classiﬁed as other (n¼185;
16%) were also enrolled.
Microbiology
Daptomycin was used empirically (i.e. before culture results were
known) in 596 (53%) patients. Methicillin-resistant S. aureus
(MRSA) was the suspected pathogen in 327 (55%) of these
patients, with methicillin-susceptible S. aureus (MSSA) suspected
in 96 (16%) patients.
Culture results were available for 1029 (91%) patients prior
to, or shortly after, initiation of daptomycin therapy (Table 2).
S. aureus was the most commonly cultured pathogen
(346 patients; 34%), with 52% of these isolates conﬁrmed as
being resistant to methicillin—a trend that was observed for all
ofthecommonlytreatedinfections.Coagulase-negativestaphylo-
cocci (CoNS), Enterococcus faecium and Enterococcus faecalis
were also among the most frequent pathogens (22%, 5% and
5% of patients for whom culture results were available, respect-
ively), although the isolation frequency of CoNS and enterococci
was higher for bacteraemia patients than for other infection
types. Vancomycin resistance was more common among
E. faecium isolates (22%) than E. faecalis isolates (6%).
Table 1. Baseline patient characteristics (N¼1127)
Characteristic Patients, n (%)
Gender
female 404 (36)
male 723 (64)
Age, mean, years (SD) 59.2 (18)
Age groups
,65 years 610 (54)
≥65 years (including ≥75 years) 514 (46)
≥75 years 237 (21)
Body weight, mean, kg (SD) 75.4 (18)
Race, Caucasian 1087 (97)
Neutropenia at baseline or during daptomycin therapy 75 (7)
Renal function
CLCR,30 mL/min 152 (14)
receiving dialysis 104 (9)
Frequent signiﬁcant underlying disease (.7%)
a
hypertension 338 (30)
diabetes mellitus 292 (26)
valvular heart disease 162 (14)
cancer 160 (14)
chronic renal failure 145 (13)
cardiac arrhythmias 141 (13)
other cardiovascular disease 133 (12)
peripheral cardiovascular disease 114 (10)
congestive heart failure 108 (10)
acute coronary syndromes 103 (9)
anaemia (all haematological disease) 83 (7)
immunosuppression 80 (7)
chronic obstructive pulmonary disease 79 (7)
Country of treatment
Spain 345 (31)
Greece 231 (21)
Germany 230 (20)
UK 183 (16)
Austria 62 (6)
Italy 53 (5)
France 8 (1)
Argentina 8 (1)
Slovenia 7 (1)
SD, standard deviation.
aPatients may have one or more underlying disease. Severity of under-
lying co-morbidities was not captured.
Table 2. Conﬁrmed primary infecting pathogens in patients for whom
culture results were obtained (N¼1029)
Organism isolated Patients, n (%)
a
S. aureus
b 346 (34)
MRSA 181 (18)
MSSA 47 (5)
Staphylococcus epidermidis 114 (11)
Other CoNS 112 (11)
E. faecium
b 50 (5)
VRE 11 (1)
non-VRE 26 (3)
E. faecalis
b 48 (5)
VRE 3 (0.3)
non-VRE 36 (4)
Other
c 131 (13)
Culture negative 212 (21)
Missing results 16 (2)
VRE, vancomycin-resistant enterococci.
aPercentage of total number of patients with culture results.
bA proportion of isolates had unknown susceptibility.
cOther pathogens include streptococci, Staphylococcus spp., Enterococcus
spp., Corynebacterium spp. and Gram-negative pathogens.
Gonzalez-Ruiz et al.
914Previous and concomitant antibiotic therapy
The majority of patients (n¼791; 70%) had received previous
antibiotic therapy for their designated primary infection, but
information regarding prior antibiotic therapy was not available
for 34 (3%) patients. Glycopeptides were the most frequently
used class of antibiotic prior to daptomycin (318 patients;
28%), vancomycin being the most common (243 patients;
22%). An oxazolidinone was also used in a high proportion of
patients (129 patients; 11%) prior to daptomycin (Table 3).
Treatment failure was the most common reason for discon-
tinuation of previous antibiotic therapy, accounting for treatment
discontinuation in 551 (49%) patients. Other common reasons
for switching therapy to daptomycin were narrowing of the anti-
biotic spectrum (17%), non-susceptible Gram-positive organisms
(13%) and toxicity/intolerance (11%). Discontinuation of prior
antibiotic therapy due to toxicity or intolerance was observed
most frequently with glycopeptides (57 of 318 patients; 18%)
and oxazolidinones (21 of 129 patients; 16%), with discontinu-
ation due to treatment failure reported for 114 (36%) patients
receiving glycopeptides and 50 (39%) patients receiving oxazoli-
dinones. The use of antibiotics concomitantly with daptomycin
was common (737 patients; 65%), and the three most frequently
used antibiotic classes were carbapenems (265 patients; 24%),
aminoglycosides (167 patients; 15%) and ﬂuoroquinolones
(155 patients; 14%).
Daptomycin prescribing patterns
Daptomycinwastheﬁrst-linetherapyfortreatmentoftheprimary
infection in 302 (27%) patients. Daptomycin was used as mono-
therapy in 117 (39%) patients receiving the drug ﬁrst line com-
pared with 227 (30%) patients receiving daptomycin as
second-line therapy. The most frequently prescribed dose of dap-
tomycinwas6 mg/kg(n¼530;47%)followedby4 mg/kg(n¼365;
32%),withonlyasmallproportionofpatientsreceivingalternative
doses (,4 mg/kg: n¼20, 2%; .6 mg/kg: n¼84, 8%; .4 mg/kg;
and ,6 mg/kg: n¼123; 11%). Doses of 4 mg/kg every 48 h (as
indicated for cSSTI patients with CLCR,30 mL/min)
1 were
recorded as 4 mg/kg. For uSSTIs, cSSTIs, UTIs, necrotizing infec-
tions and metastatic abscess, the most frequently used dose
was 4 mg/kg (46%, 47%, 56%, 60% and 100%, respectively). A
dose of 6 mg/kg was the most frequently used for bacteraemia
(61%), IE (65%), foreign body/prosthetic infection (52%), osteo-
myelitis (69%), septic arthritis (57%), necrotizing fasciitis (60%)
and surgical prophylaxis (50%).
The median duration of daptomycin therapy was 10 days
(range 1–246 days) in the inpatient setting (n¼1097), with
326 of these patients receiving daptomycin in an intensive care
unit for a median duration of 8 days (range 1–90 days). Patients
with IE received daptomycin for the longest median duration
(16 days; range 1–112 days) whereas the shortest median dur-
ation of treatment was for uSSTIs (7 days; range 1–28 days)
and UTIs (7 days; range 3–18 days). For patients treated in the
outpatient setting (n¼153), either exclusively or in combination
with the inpatient setting, the median duration of outpatient
therapy was 13 days (range 2–189 days).
The most common reason for discontinuation of daptomycin
therapy was that therapy was completed as needed (639
patients; 57%), and 251 (22%) patients de-escalated therapy
to an oral or alternative parenteral agent after clinical improve-
ment. Discontinuation due to treatment failure was reported
for 3% of patients (n¼31) whereas in 4% of patients (n¼48)
the primary reason for discontinuation was due to AEs (see
Safety and tolerability section below). The primary reason for dis-
continuation could not be determined for 5% of patients (n¼60)
and was recorded as ‘other’ for 9% of patients (n¼98).
Clinical outcome
Overall, daptomycin treatment was associated with a clinical
success rate of 79% (894/1127), and the overall rateof treatment
failure was 7.5% (Figure 1). Clinical success rates were highest
(.80%) for uSSTIs, endocarditis and cSSTIs, and lowest for infec-
tions categorized as other (foreign body/prosthetic infection and
UTI, among others). Similarly low failure rates were observed
regardless of whether daptomycin was administered as ﬁrst- or
second-line therapy [6% (19/302) versus 8% (60/791), respect-
ively]. The clinical success rate with second-line daptomycin
[77% (611/791)] was lower than that when daptomycin was
used as ﬁrst-line therapy [85% (257/302)], although there were
more non-evaluable patients in the group receiving daptomycin
second line compared with ﬁrst line [15% (120/791) versus 9%
(26/302), respectively].
Table 3. Most frequently (.10%) used antibiotics prior to daptomycin therapy (N¼1127)
Antibiotic
Patients,
n (%)
a
Duration, median days
(range)
Reason for discontinuation, n (%)
b
failure
antibiotic spectrum
narrowed
non-susceptible Gram-positive
organism
toxicity/
intolerance
Glycopeptide 318 (28) 7 (1–60) 114 (36) 30 (9) 16 (5) 57 (18)
Penicillin 297 (26) 5 (1–70) 91 (31) 31 (10) 35 (12) 10 (3)
Fluoroquinolone 174 (15) 7 (1–242) 68 (39) 18 (10) 22 (13) 2 (1)
Carbapenem 169 (15) 10 (1–180) 44 (26) 18 (11) 14 (8) 2 (1)
Aminoglycoside 164 (15) 6 (1–62) 32 (20) 15 (9) 13 (8) 19 (12)
Cephalosporin 137 (12) 4 (1–56) 42 (31) 19 (14) 15 (11) 3 (2)
Oxazolidinone 129 (11) 9 (1–64) 50 (39) 9 (7) 6 (5) 21 (16)
aPercentage of the safety population.
bPercentage of the population of patients that received the speciﬁc drug.
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pathogen, rates of clinical success were similar regardless of
whether daptomycin was used as ﬁrst- (N¼53) or second-
(N¼134) line therapy: 83% and 80%, respectively. Failure rates
were 11% in both groups (6/53 and 15/134 for ﬁrst- and second-
line therapy, respectively). The mean time to clinical improve-
ment was determined for 632 patients deemed to have
improved clinically and was 6.3 (standard deviation¼8.3) days.
Safety and tolerability
The safety proﬁle of daptomycin was favourable. AEs were
reported for 193 (17%) patients, and 109 (10%) patients experi-
enced an SAE. Infections and infestations were the most fre-
quently reported system organ class among all AEs (5%) and
SAEs (4%). Septic shock was the most commonly reported AE
(2%), which reﬂects the severity of infections treated in the reg-
istry. AEs resulting in discontinuation (regardless of the relation-
ship to daptomycin) occurred in 51 (5%) patients. The most
frequent AEs leading to discontinuation were septic shock (six
patients) and increases in blood CPK (six patients). In total, 89
(8%) patients experienced AEs requiring signiﬁcant additional
therapy, most frequently due to infection or infestation (n¼28;
3%); these included septic shock (0.6%), pneumonia (0.4%)
and urinary tract infections (0.4%), as well as various Gram-
negative and fungal infections. Eighty-ﬁve (8%) patients died
while receiving daptomycin therapy—the principal cause of
death was infection and infestation (4%, n¼41), of which
septic shock (2%, n¼19) was the most frequent.
There was no increase in the proportion of patients with
CLCR,30 mL/min from initiation [152 patients (14%)] to the
end of therapy [151 patients (13%)]. Serum CPK was measured
at baseline for 614 (55%) patients and during the course of dap-
tomycin therapy for 617 (55%) patients (Figure 2). At baseline
among patients with CPK measured, serum CPK concentrations
below or equal to the upper limit of normal (ULN) were reported
for 498 (81%) patients, .5–10× ULN in nine (1%) patients and
.10× ULN in 14 (1%) patients. During therapy, 459 (74%)
patients had a peak serum CPK concentration below or equal
to the ULN. CPK elevations .5–10× ULN and .10× ULN were
observed in 21 (3%) and 27 (4%) patients, respectively. The
mean and median time to highest CPK concentrations was
11 days after initiation of treatment with daptomycin. Elevated
CPK concentration was reported as an SAE in only one patient.
Although the patient had severe renal impairment at baseline
(CLCR,30 mL/min), the daptomycin dosing interval was not
adjusted at the start of therapy. Daptomycin treatment at
6 mg/kgoncedailywasinitiatedforcatheter-relatedMRSAbacter-
aemiaandleft-sidedIEinthiscriticallyillpatientcomplicatedwith
haemorrhagic shock. Later the daptomycin dosing interval was
0
≤1 × ULN >1–2 × ULN >2–5 × ULN >5–10 × ULN >10 × ULN
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Figure 2. Baseline and peak serum CPK concentrations. *Values for 16 patients are unknown.
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Figure 1. Treatment outcomes by primary infection type (N¼1127). Data were missing for two patients. *Clinical success: cure or improved outcomes.
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916corrected to dosing every 48 h, as recommended in the current
label. This patient had a CPK concentration of .5–10× ULN on
day 10 of daptomycin therapy, possibly related to daptomycin,
but no AEs indicative of musculoskeletal and connective tissue
disorders were reported. Daptomycin therapy was not discontin-
ued and the outcome of the patient’s infection was cured. It is
relevant to note in this case that the European label, in contrast
to the USA, did not have a dose recommendation for the 6 mg/kg
dose at the time this patient was treated. The European approval
for the 6 mg/kg dose in patients with CLCR,30 mL/min (dose
interval 48 h) was obtained in 2010.
SAEs concerning musculoskeletal and connective tissue dis-
orders related to daptomycin were reported in only one patient.
Again, although severe renal impairment (CLCR,30 mL/min)
was a baseline condition, the daptomycin dosing interval
was not adjusted. The patient was treated with daptomycin at
6 mg/kg once daily for 10 days in the outpatient setting to treat
an MRSA infection following hip surgery. After 10 days of
therapy, CPK elevation (.10×ULN) accompanied by muscle pain
werereportedwithaclinicaldiagnosisofrhabdomyolysis,possibly
related to daptomycin. Daptomycin treatment was discontinued
and the patient recovered.
Discussion
These data show that, during the study period (2006–08), dap-
tomycin was used in Europe and Argentina to treat a variety of
Gram-positive infections in a severely ill patient population with
multiple co-morbidities, who were commonly infected with
drug-resistant pathogens (MRSA, CoNS and vancomycin-resistant
enterococci), and almost half of whom were aged ≥65 years.
Daptomycin demonstrated a favourable safety and tolerability
proﬁle and low overall rates of clinical failure similar to the
early results from the CORE database in the USA,
10–13 despite
its use in this severely ill population, frequently as second-line
or salvage therapy. Although just over half of the patients
received daptomycin empirically, .90% of infections overall
were microbiologically documented: staphylococcal species
were identiﬁed in more than half of patients in whom an infect-
ing pathogen was isolated. MRSA and CoNS were predominant,
accounting for  40% of all isolates. The most frequently
treated infections were those for which daptomycin is indicated
(cSSTIs and bacteraemia); however, additional non-registered
Gram-positive infections were treated (including osteomyelitis),
probably reﬂecting an unmet need for licensed treatment
options for these diseases. Only eight patients from Argentina
were included; therefore, the reported results largely reﬂect
European use of the drug.
The initial dosing in Europe appears to have been higher than
was being used initially in the USA. During the ﬁrst 2 years of the
CORE database (2004–06), the median initial dose of daptomy-
cin administered was 4 mg/kg (range 2–12 mg/kg).
14 In
EU-CORE, the majority of patients received doses of .4 mg/kg,
appearing to correspond to the severity of the type of infections
being treated. This could reﬂect increased conﬁdence with the
use of daptomycin following the publication of the initial
results from CORE in 2007,
10–13in addition to the Phase III clini-
cal trial results in SAB with or without IE in 2006,
7 demonstrat-
ing the safety and efﬁcacy of the 6 mg/kg dose in these
infections. Furthermore, inclusion of higher than approved
doses of daptomycin in treatment guidelines may, in part,
account for the use of doses of .6 mg/kg in a small proportion
of patients.
15,16
Daptomycin was typically used as second-line therapy.
Notably,ahighproportion( 40%)hadreceivedeitheraglycopep-
tide(mostcommonlyvancomycin)oroxazolidinoneagent(linezo-
lid)priortoreceivingdaptomycin,andmorethanhalfofthesehad
switched to daptomycin as a consequence of treatment failure,
toxicity or intolerance. Daptomycin has an important role as ﬁrst-
line therapy for Gram-positive infections, in terms of both efﬁcacy
and cost considerations, the beneﬁt of which is supported by the
results observed here.
17 Although patients receiving daptomycin
ﬁrstlinehadnumericallyhigherclinicalsuccessratesthanpatients
receiving daptomycin second line, the uneven numbers of
non-evaluable patients between these groups confounds this
comparison. Comparison of the failure rates indicates only a 2%
difference in treatment failure between the two patient groups.
Unlike glycopeptides, daptomycin has proven similar efﬁcacy
against both MRSA and MSSA,
6,7 making it an attractive option
for empirical therapy of suspected S. aureus infections regardless
of methicillin resistance risk. Unlike linezolid, daptomycin is bac-
tericidal, which is expected to confer advantages in terms of efﬁ-
cacy, especially in serious infections.
18–20 Experience in EU-CORE
appears to support this concept, with 53% of patients receiving
daptomycin as empirical therapy.
There is emerging evidence that daptomycin is being used to
treat infections caused by other Gram-positive species that are of
increasing importance in hospital and outpatient practice,
21–23
particularly in orthopaedic-related and endovascular infections
where other long-term treatment options may be limited.
24,25
In addition, alternative therapies are increasingly required to
face current trends of rising vancomycin resistance, as demon-
strated by the high rate of vancomycin resistance among enter-
ococci in this study (22% in E. faecium). This is also reﬂected in
published treatment guidelines where daptomycin is rec-
ommended as ﬁrst alternative to vancomycin when the vanco-
mycin MIC is no longer associated with a signiﬁcant chance of
clinical success.
15,16
Prior to optimization of the dosing interval to a once-daily
regimen, daptomycin had been associated with reversible CPK
elevation and skeletal muscle toxicity.
26 However, in clinical
trials with once-daily dosing, daptomycin-associated CPK
elevations were demonstrated in 7% of patients receiving the
6 mg/kg dose, only leading to discontinuation of daptomycin in
2.5% of patients, and did not occur in patients receiving the
4 mg/kg dose.
6,7 In agreement with these clinical trial ﬁndings,
analysis of the EU-CORE database has shown that daptomycin
therapy minimally impacts upon serum CPK concentrations as
reﬂected in the low rates of related AEs and discontinuations.
It is, however, important to keep in mind that the dosing interval
in patients with severe renal impairment (CLCR,30 mL/min)
with or without dialysis should be adjusted to 48 h for both
approved doses.
Concomitant administration of other antibiotic agents with
daptomycin was common, and aminoglycosides were among
the most frequent with concomitant use in 15% of patients.
Although aminoglycosides are typically associated with nephro-
toxicity,
27 the rate of renal and urinary SAEs was very low (1%)
overall. This rate was similar to that observed for daptomycin
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however, it must be noted that in the pivotal trial, comparator
therapy (vancomycin or anti-staphylococcal penicillin, in combi-
nation with short-course gentamicin) was associated with signiﬁ-
cantly higher rates of these SAEs (8%; P¼0.009).
7 In animal
models,daptomycinhasbeenshowntoattenuatethenephrotoxi-
cityinducedbytheadministrationofgentamicin,leadingtopostu-
lation that daptomycin may in fact have nephron-protective
properties.
28
Even though the median treatment duration of inpatient
therapy was 10 days, 30 (3%) patients were treated with dapto-
mycin in the inpatient setting for .42 days, and the maximum
treatment duration documented for an individual patient was
246 days. Most of the patients receiving prolonged therapy had
various signiﬁcant underlying diseases, but in this patient group
only two patients had AEs reported as possibly related to dapto-
mycin with no SAEs reported. There are relatively few treatment
options available for resistant Gram-positive infections that can
be used for long treatment durations without an increased risk
of AEs; e.g. myelosuppression and peripheral neuropathy have
been related to treatment duration with linezolid, and the
maximum recommended treatment duration with this agent is
28 days.
29 Daptomycin might, therefore, represent a useful
option for the treatment of chronic complicated infections
where extended duration of therapy is required, such as osteoar-
ticular or endovascular infections.
The EU-CORE registry, by its nature, has inherent limitations
in that data collection is retrospective, non-comparative, non-
blinded and non-randomized, and clinical outcomes are
judged by the attending clinician. Although a potential selection
bias cannot be excluded, the fact that the study does not
include any clinical criterion for patient inclusion (except partici-
pation in interventional studies with daptomycin) and is per-
formed in a very large number of participating institutions
without restrictions does give credibility to its results. A
central laboratory was not used in this registry and therefore
site-to-site differences in the quality of microbiological results
and other laboratory results cannot be excluded. This registry
allows the inclusion of diverse infections and the use of conco-
mitant antibiotics, including broad-spectrum antibiotics. There-
fore, the efﬁcacy results are to be interpreted in this context.
Despite these limitations, the data collected in EU-CORE
provide a useful insight into real-world clinical practice and
expand on the evidence base derived from clinical trials. In
this kind of registry, clinical information can be obtained from
patient populations that urgently need treatment but would
otherwise have been excluded from controlled clinical trials
due to their baseline conditions,
8 as was the case for patients
with severe renal insufﬁciency in the pivotal trials for cSSTI
and SAB/IE.
6,7 The current results are of interest for physicians
in different parts of the world, and it is planned to further
expand this registry to other continents.
The current results suggest that daptomycin has a relevant
role in the therapeutic armamentarium of European physicians
for the treatment of Gram-positive infections.
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